Sandoz Group (OTCMKTS:SDZNY) Shares Up 1.6% - Here's Why

Key Points

• Sandoz Group's shares increased by 1.6% during trading, reaching a last price of $63.11, after previously closing at $62.12.
• Analysts have mixed views on Sandoz Group, with Jefferies downgrading the stock from "strong-buy" to "hold", while Royal Bank of Canada upgraded it from "hold" to "moderate buy".
• The company's debt-to-equity ratio stands at 0.57, and its quick and current ratios are 0.79 and 1.24 respectively, indicating a solid financial health.

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report)'s stock price traded up 1.6% during mid-day trading on Wednesday . The company traded as high as $63.19 and last traded at $63.11. 19,997 shares traded hands during mid-day trading, a decline of 13% from the average session volume of 22,963 shares. The stock had previously closed at $62.12.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Royal Bank Of Canada raised shares of Sandoz Group from a "hold" rating to a "moderate buy" rating in a research note on Friday, May 2nd. Jefferies Financial Group cut shares of Sandoz Group from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 8th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Sandoz Group presently has a consensus rating of "Hold".

Sandoz Group Trading Down 0.2%

The business's 50 day simple moving average is $57.78 and its two-hundred day simple moving average is $49.50. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.79 and a current ratio of 1.24.

Sandoz Group Company Profile

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.